Skip to main content
Healthcare

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

Feed excerpt — reported by STAT News

A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.